HomeCompareZYXI vs CL

ZYXI vs CL: Dividend Comparison 2026

ZYXI yields 3636.36% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZYXI wins by $136.97M in total portfolio value
10 years
ZYXI
ZYXI
● Live price
3636.36%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$137.01M
Annual income
$2,429,517.95
Full ZYXI calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — ZYXI vs CL

📍 ZYXI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZYXICL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZYXI + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZYXI pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZYXI
Annual income on $10K today (after 15% tax)
$309,090.91/yr
After 10yr DRIP, annual income (after tax)
$2,065,090.26/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, ZYXI beats the other by $2,060,498.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZYXI + CL for your $10,000?

ZYXI: 50%CL: 50%
100% CL50/50100% ZYXI
Portfolio after 10yr
$68.53M
Annual income
$1,217,459.95/yr
Blended yield
1.78%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

ZYXI
Analyst Ratings
6
Buy
3
Hold
Consensus: Buy
Price Target
$14.38
+26045.5% upside vs current
Range: $11.00 — $18.00
Altman Z
-5.0
Piotroski
3/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZYXI buys
0
CL buys
0
No recent congressional trades found for ZYXI or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZYXICL
Forward yield3636.36%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28.6%
Portfolio after 10y$137.01M$40.8K
Annual income after 10y$2,429,517.95$5,401.96
Total dividends collected$101.63M$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$14.38$92.45

Year-by-year: ZYXI vs CL ($10,000, DRIP)

YearZYXI PortfolioZYXI Income/yrCL PortfolioCL Income/yrGap
1← crossover$192,518$181,818.18$11,012$312.01+$181.5KZYXI
2$1,841,663$1,635,668.49$12,196$412.95+$1.83MZYXI
3$9,282,305$7,311,726.11$13,599$549.66+$9.27MZYXI
4$27,152,808$17,220,741.46$15,288$736.64+$27.14MZYXI
5$52,592,991$23,539,485.74$17,353$995.28+$52.58MZYXI
6$77,580,225$21,305,724.70$19,926$1,357.80+$77.56MZYXI
7$97,696,914$14,686,073.70$23,194$1,873.82+$97.67MZYXI
8$113,177,847$8,642,148.87$27,439$2,621.52+$113.15MZYXI
9$125,778,601$4,678,305.21$33,088$3,727.38+$125.75MZYXI
10$137,012,622$2,429,517.95$40,806$5,401.96+$136.97MZYXI

ZYXI vs CL: Complete Analysis 2026

ZYXIStock

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Full ZYXI Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this ZYXI vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZYXI vs SCHDZYXI vs JEPIZYXI vs OZYXI vs KOZYXI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.